These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 27520485)

  • 21. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
    Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
    Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
    Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
    Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element.
    Li JJ; Dong Z; Dawson MI; Colburn NH
    Cancer Res; 1996 Feb; 56(3):483-9. PubMed ID: 8564958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
    Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
    Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.
    Roberts TC; Etxaniz U; Dall'Agnese A; Wu SY; Chiang CM; Brennan PE; Wood MJA; Puri PL
    Sci Rep; 2017 Jul; 7(1):6153. PubMed ID: 28733670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells.
    Khan YM; Kirkham P; Barnes PJ; Adcock IM
    PLoS One; 2014; 9(4):e95051. PubMed ID: 24759736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.
    Roe JS; Mercan F; Rivera K; Pappin DJ; Vakoc CR
    Mol Cell; 2015 Jun; 58(6):1028-39. PubMed ID: 25982114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Requirement and epigenetics reprogramming of Nrf2 in suppression of tumor promoter TPA-induced mouse skin cell transformation by sulforaphane.
    Su ZY; Zhang C; Lee JH; Shu L; Wu TY; Khor TO; Conney AH; Lu YP; Kong AN
    Cancer Prev Res (Phila); 2014 Mar; 7(3):319-29. PubMed ID: 24441674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.
    Kokkola T; Suuronen T; Pesonen M; Filippakopoulos P; Salminen A; Jarho EM; Lahtela-Kakkonen M
    Chembiochem; 2015 Sep; 16(14):1997-2001. PubMed ID: 26212199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BET Bromodomain Inhibition Potentiates Ocular Melanoma Therapy by Inducing Cell Cycle Arrest.
    Chen X; Huang R; Zhang Z; Song X; Shen J; Wu Q
    Invest Ophthalmol Vis Sci; 2024 Jul; 65(8):11. PubMed ID: 38967943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes.
    Dong Z; Crawford HC; Lavrovsky V; Taub D; Watts R; Matrisian LM; Colburn NH
    Mol Carcinog; 1997 Jul; 19(3):204-12. PubMed ID: 9254887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
    Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
    J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triterpenoid corosolic acid modulates global CpG methylation and transcriptome of tumor promotor TPA induced mouse epidermal JB6 P+ cells.
    Hudlikar RR; Sargsyan D; Wu R; Su S; Zheng M; Kong AN
    Chem Biol Interact; 2020 Apr; 321():109025. PubMed ID: 32135139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.